All Stories

Corcept’s investigational oral therapy cuts ovarian cancer progression by 30%, teeing up FDA filing

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone.

Mar 31, 2025 - 15:51
 0
Corcept’s investigational oral therapy cuts ovarian cancer progression by 30%, teeing up FDA filing
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone.
Read More

Tags:

Previous Article

FedEx grows ATR feeder fleet amid air network overhaul

Next Article

Google DeepMind’s drug discovery spin-off Isomorphic Labs raises $600mn

Related Posts

VC firm Sofinnova brings in €1.6B over a year to fund up to 60 life sciences companies

VC firm Sofinnova brings in €1.6B over a year to fund u...

Mar 4, 2025  0

GSK plans to move vaccine R&D center from Rockville, Maryland, to the Boston area

GSK plans to move vaccine R&D center from Rockville, Ma...

Feb 12, 2025  0

Pfizer, Flagship tap Valo Health for autoimmune offshoot of multibillion-dollar collab

Pfizer, Flagship tap Valo Health for autoimmune offshoo...

Apr 1, 2025  0